Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson vs Adenosine Stress

NACompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

June 30, 2012

Conditions
Coronary Artery Disease
Interventions
DRUG

Regadenoson

Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.

DRUG

Adenosine

Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.

DRUG

N-13 ammonia

Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

lead

Mayo Clinic

OTHER